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Abstract
Background: Earlier studies showed that 17b-estradiol (E2), an endogenous female sex hormone, can bind to human protein
disulfide isomerase (PDI), a protein folding catalyst for disulfide bond formation and rearrangement. This binding interaction
can modulate the intracellular levels of E2 and its biological actions. However, the structure of PDI’s E2-binding site is still
unclear at present, which is the focus of this study.
Methodology/Principal Findings: The E2-binding site structure of human PDI was studied by using various biochemical
approaches coupled with radiometric receptor-binding assays, site-directed mutagenesis, and molecular computational
modeling. Analysis of various PDI protein fragments showed that the [
3H]E2-binding activity is not associated with the single
b or b’ domain but is associated with the b-b’ domain combination. Computational docking analyses predicted that the E2-
binding site is located in a hydrophobic pocket composed mainly of the b’ domain and partially of the b domain. A
hydrogen bond, formed between the 3-hydroxyl group of E2 and His256 of PDI is critical for the binding interaction. This
binding model was jointly confirmed by a series of detailed experiments, including site-directed mutagenesis of the His256
residue coupled with selective modifications of the ligand structures to alter the binding interaction.
Conclusions/Significance: The results of this study elucidated the structural basis for the PDI–E2 binding interaction and the
reservoir role of PDI in modulating the intracellular E2 levels. The identified PDI E2-binding site is quite different from its
known peptide binding sites. Given that PDI is a potential therapeutic target for cancer chemotherapy and HIV prevention
and that E2 can inhibit PDI activity in vitro, the E2-binding site structure of human PDI determined here offers structural
insights which may aid in the rational design of novel PDI inhibitors.
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Introduction
Protein disulfide isomerase (PDI) is a 57-kDa oxidoreductase of
the thioredoxin superfamily that is expressed mainly in the
endoplasmic reticulum (ER) of eukaryotic cells. This protein plays
a vital role in the folding of many proteins in the ER by serving as
a catalyst of disulfide rearrangements (isomerase activity), disulfide
formation (oxidase activity), and disulfide reduction (reductase
activity) [1–5]. In addition, studies have shown that PDI is also
involved in many other important biological processes, such as
viral infection (e.g., HIV-1 fusogenic events), through its reduction
of the disulfide bonds in toxin and related factors [6,7], ER stress
response [8,9], and others.
Besides serving as a protein folding catalyst, a number of studies
have shown that PDI can also serve as an intracellular binding
protein for certain small molecules that contain a phenolic
structure, which includes both endogenous hormones (estrogens
[10] and thyroid hormones [11,12]) and environmental chemicals
(e.g., endocrine disruptors) [13]. It has been suggested [12] that
PDI, owing to its unusually high levels present in various types of
cells in rodents as well as humans, may function as an effective
intracellular reservoir for estrogenic hormones and thus may
modulate their intracellular availability as well as total content in
target cells. This concept was supported by our recent study
showing that PDI can modulate the intracellular levels of 17b-
estradiol (E2) in human breast cancer cells, augment its hormonal
activity, and slow down its metabolic disposition [14]. Given
that E2 is an important female sex hormone and plays vital
physiological roles in the human body [15,16] and that PDI is
ubiquitously expressed in various cells and tissues [17,18], it is
expected that PDI may serve as a global modulator of the
intracellular levels and actions of E2 in humans. On the other
hand, the observed ability of E2 and particularly some of its
structural analogs to interact with human PDI may also have
pharmacological relevance given that some of these compounds
can effectively inhibit PDI’s catalytic activity in vitro [10,12,13,19]
and that PDI has received considerable attention in recent years as
a potential therapeutic target in cancer chemotherapy [20,21] and
HIV prevention [22–25].
At present, the E2-binding site structure of human PDI is not
known. The main purpose of our present study, therefore, was to
delineate the structural basis of human PDI’s E2-binding activity.
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coupled with radiometric ligand-receptor binding assays, compu-
tational modeling, site-directed mutagenesis, and selective ligand
modifications, we located the PDI’s E2-binding site to a
hydrophobic pocket between the b and b’ domains. In addition,
we have built the PDI-E2 binding model, and identified a critical
hydrogen bond formed between PDI-His256 and the 3-hydroxyl
group of E2. This is the first characterization of the E2-binding site
structure of human PDI. The findings offer mechanistic insights at
the molecular level concerning the structural basis of the PDI–E2
binding interaction and its reservoir role in modulating the
intracellular E2 levels.
Results
Biochemical characterization of the E2-binding site in
human PDI protein
Recently, we have characterized the E2-binding site structure of
human PDIp [26], which shares similar domain architecture with
human PDI [27]. Both PDI and PDIp are multi-domain proteins
composed of four thioredoxin-like domains, a, b, b’ and a’, plus a
small linker region x between b’ and a’ and a C-terminal acidic
extension c (as depicted in Figure 1A). We hypothesized that
human PDI may have a similar E2-binding site structure as that of
human PDIp, which binds E2 in a hydrophobic pocket between its
b and b’ domains [28]. To test this hypothesis, we first designed
two truncated human PDI fragments (namely, a-b and b-b’), with a
histidine tag attached to their N-termini for the convenience of
purification, and then their [
3H]E2-binding activities were
determined and compared with that of the full-length human
PDI protein. After these two PDI fragments were cloned and
selectively expressed in E. coli cells (left part in Figure 1B), they
were purified (Figure 1D). Radiometric [
3H]E2-binding assay
using whole cell lysates (Figure 1C) and purified proteins
(Figure 1E) both showed that the b-b’ fragment can bind E2 as
does the full-length protein. However, no binding activity was
detected for the a-b fragment when it was assayed under the same
conditions. In addition, we have also prepared several other PDI
fragments that contain the a’ domain, including b’-x-a’, x-a’-c,
b’(C)-x-a’-c, and b’(BC)-x-a’-c (for structures of these fragments, see
Figure 1A), to test their potential [
3H]E2-binding activity. As
shown in Figure S1C, none of them was found to have any
appreciable [
3H]E2-binding activity. Together, these results clearly
suggest that the E2-binding site is only associated with the b-b’
fragment.
Next, we selectively expressed the single b and b’ domains
for testing their individual E2-binding activity. In our initial
experiments, we also adopted the same strategy of attaching a
histidine tag to the single domain fragment. However, we did not
observe any E2-binding activity for these histidine-tagged single
domain proteins (Figure S1C). To confirm this negative result, we
also prepared the GST-tagged b and b’ fusion proteins, in which
GST, as a structurally more stable protein, might help these small
protein fragments fold better and thus better exert their potential
E2-binding activity. The cell lysates containing the GST-tagged b
or b’ domain (Figure 1F, lane 2, 3) also did not exhibit any
appreciable [
3H]E2-binding activity (Figure 1G). The failure of the
GST fusion proteins to bind [
3H]E2 is not due to the potential
interference of the GST tag because the GST-tagged b-b’ fragment
(Figure 1F, lane 4) retains strong [
3H]E2-binding activity
(Figure 1G). Collectively, these observations suggest that the intact
E2-binding site of PDI is not associated with the single b or b’
domain but is associated with the natural b and b’ domain
combination (i.e., the b-b’ fragment).
To further probe the intactness of the E2-binding site in the b-b’
fragment, we compared its E2-binding affinity (i.e., the Kd value)
with the full-length PDI protein. The in vitro equilibrium dialysis
assay showed that the apparent Kd values for [
3H]E2 binding
(calculated according to their Scatchard plots) are 405682 nM for
the full-length protein (Figure 2A) and 535686 nM for the b-b’
fragment (Figure 2B). The difference in the estimated Kd values of
the full-length human PDI protein and its b-b’ fragment for [
3H]E2
binding is not statistically significant. Based on their Scatchard
plots, it is apparent that both PDI and its b-b’ fragment exhibited
single binding site kinetics, suggesting that each of them only has a
single E2-binding site. Here it is also of note that the binding
affinity of PDI for E2 as determined in this study is higher than
that reported earlier [12], likely due, in part, to the different
incubation temperatures used in these binding assays, and/or to
different PDI species used (human PDI in this study and rat PDI in
the earlier study).
Computational docking analysis of the E2-binding site
structure of PDI b-b’ fragment
Because the E2-binding site is only associated with the b-b’
fragment and also because the b-b’ fragment has the same E2-
binding affinity as that of the full-length PDI, we thus used the
known PDI b-b’ fragment structure [28] for computational docking
analysis to probe the E2-binding site structure. First, we used the
Insight II modeling program to search for the cavities present in the
protein structure. Four cavities were found in the b-b’ fragment
(Figure S3): cavity I is located between the b and b’ domains, i.e.,i t
is formed jointly by these two domains (cavity size = 300 A ˚ 3). In
comparison, cavity IV is solely formed by the b domain, and cavity
II and cavity III are solely formed by the b’ domain. Since the
location of cavities II, III and IV in the single b’ or b domain is not
supported by the biochemical results (shown in Figure 1 and S1),
they were not further studied. Instead, cavity I was the only cavity
that was selected for computational docking analysis of its binding
interaction with E2.
The overall E2-PDI binding interaction as revealed by docking
analysis is shown in Figure 3A and 3B, and the amino acid
residues surrounding the binding pocket are shown in Figure 3C.
A few features can be readily drawn from this binding model
(Figure 3B, 3C, 3D). First, one hydrogen bond is formed between
the 3-hydroxyl group of E2 and the nitrogen atom of PDI-His256,
whereas no hydrogen bond is formed between the 17-hydroxyl
group of E2 and PDI. In this respect, the E2-PDI interaction is
quite similar to the E2-PDIp interaction [26]. Second, the major
binding site is contributed by the hydrophobic residues, which
provide strong hydrophobic interactions with the four aliphatic
rings of E2. Most of the hydrophobic residues are from the b’
domain (i.e., F228, L234, L236, I238, L287, and I248), while only
one is from the b domain (F228). Third, the polar residues
surrounding the binding site are mainly from the b’ domain (i.e.,
H231, N232, P235, K254, H256, K283, and G284), but the b
domain (i.e., K207, E211, and N214) also contributes, to certain
degrees. Together, the computational docking results show that
the b’ domain provides the principal E2-binding site whereas the b
domain plays a relatively minor role.
Role of the hydrogen bond between 3-hydroxyl group of
E2 and His256
To experimentally test the binding model as suggested by our
computational docking analysis, we first sought to determine
whether the identified amino acid residue, His256, is indeed
involved in the binding interactions between PDI and E2 through
Estradiol-Binding Site Structure of PDI
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side-chain length of leucine is similar to that of histidine but the
former does not contain electro-negative atoms that are necessary
for the formation of hydrogen bonds. Therefore, we mutated
His256 to leucine (H256L). As shown in Figure 4A and 4B, neither
the whole cell lysates that contain the full-length H256L mutant
PDI protein nor the purified mutant protein retain any
appreciable [
3H]E2-binding activity when compared with the
wild-type PDI protein. The radiometric ligand-receptor binding
assay further confirmed that this mutant protein does not have an
appreciable [
3H]E2-binding activity even when very high
concentrations of [
3H]E2 are present (Figure 4C). Similarly, we
Figure 1. Both PDI and its b-b’ fragment can bind E2. (A). Domain organization of the human PDI protein. The letters A, B and C in boxes that
represent the b-a-b, a-b-a, and b-b-a secondary-structure elements, respectively, of the thioredoxin fold, are adopted from an earlier study [40] and
were used to guide the design of various PDI protein fragments as shown in this figure and Figure S1. (B) and (D). SDS-PAGE analysis of two histidine-
tagged PDI fragments and the full-length protein, which were selectively expressed in E. coli cells (panel B) and then purified using affinity
chromatography (panel D). (C) and (E). The binding of [
3H]E2 by either cell lysates (at a final protein concentration of 1 mg/mL; panel C) or by purified
proteins (at a final concentration of 0.5 mM; panel E) after incubation with 4.5 nM [
3H]E2 in the absence or presence of 10 mM non-radioactive E2.
(F). SDS-PAGE analysis of selectively-expressed GST-tagged PDI protein fragments in E. coli cells. (G). The binding of [
3H]E2 by cell lysates containing
the GST-tagged PDI fragments. For the quantitative data, each value is the mean 6 S.D. of triplicate determinations.
doi:10.1371/journal.pone.0027185.g001
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that this mutant fragment does not have any [
3H]E2-binding
activity (data not shown). Taken together, these data clearly show
that the His256 residue of human PDI is indispensable for its
binding interaction with E2.
To provide further experimental support for the conclusion
derived from the mutagenesis experiments, we employed an
alternative approach by using a number of E2 derivatives that
share the same core structure as E2 but with their C-3 or C-17
hydroxyl group selectively modified such that they cannot form the
same type of hydrogen bonds with human PDI as does E2. In these
experiments, the purified full-length human PDI protein was used
as a binding protein to evaluate the ability of these structurally-
modified E2 derivatives to compete off the binding of [
3H]E2.W e
found that E1,E 3, and C2, all of which contain an intact 3-
hydroxyl group but differ in their 17-position substitutions
(structures shown in Figure 5A), can efficiently compete with
[
3H]E2 for binding to the full-length PDI (Figure 5B). This
observation is consistent with the computational modeling data,
which predicted that the 17-hydroxyl group of E2 is not important
for its binding interaction with human PDI. In contrast, C3, which
lacks the 3-hydroxyl group (Figure 5A), does not have any
appreciable activity to compete with [
3H]E2 for PDI binding
(Figure 5B). Again, this result is also fully consistent with the
computational model, i.e., the 3-hydroxyl group of E2 is crucial for
PDI-E2 binding interaction through forming a hydrogen bond
with PDI-His256.
Lastly, it is of note that in the binding model as shown in
Figure 3, the 3-hydroxyl group of E2 is a hydrogen bond donor
rather than an acceptor, while the nitrogen atom of PDI-His256 is
a hydrogen bond acceptor rather than a donor. Evidence in
support of this computational prediction came from the experi-
Figure 2. Determination of the dissociation constant (Kd) of the full-length human PDI protein (A) and its b-b’ fragment (B) for E2.
Equilibrium analysis was used to determine the dissociation constants as described in the Materials and Methods section. The concentrations of free
and total [
3H]E2 (i.e., the sum of PDI-bound [
3H]E2 and free [
3H]E2) were determined by scintillation counting calibrated against standard
concentrations of [
3H]E2 (see Figure S2B). Total [
3H]E2 subtracted by free [
3H]E2 gives rise to PDI-bound [
3H]E2. The upper right insets show the
binding curves were obtained using curve regression analysis (hyperbola model) of the SigmaPlot software. Each value is the mean of duplicate
determinations.
doi:10.1371/journal.pone.0027185.g002
Estradiol-Binding Site Structure of PDI
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diol (structure shown in Figure 5A as C1) for human PDI.
Theoretically, the oxygen atom in the 3-methoxyl group of this E2
derivative can only serve as a hydrogen bond acceptor but not a
hydrogen bond donor in forming hydrogen bonds. As expected,
computational docking analysis showed that 3-methoxyestradiol
can still bind comfortably inside the binding pocket in nearly the
same manner as does E2, suggesting that its larger 3-methoxyl
Figure 3. Docking analysis of the binding interaction of E2 inside human PDI b-b’ fragment. (A). Overview of the docking result of the E2
binding in the PDI b-b’ fragment. E2 and His256 are shown in the ball-and-stick format and colored according to atoms. The protein structure is
shown in ribbon. Yellow colored region denotes the b domain and magenta colored region denotes the b’ domain. Secondary structural elements are
labeled according the NMR structure of the fragment. (B). A close-up view of the docking result of the E2-PDI binding mode, showing that a hydrogen
bond (by green dash) is formed between the 3-hydroxyl group of E2 (a hydrogen bond donor) and PDI-His256 (a hydrogen bond acceptor).
(C). Interaction of E2 with the amino acid residues inside the binding pocket. Labeling of amino acid residues is shown in yellow for the b domain and
in magenta for the b’ domain. E2 molecule is colored in yellow. Amino acid residues are shown in the ball-and-stick format and colored according to
atoms, i.e., green for carbon, red for oxygen, white for hydrogen, and blue for nitrogen. (D). Plots of the docking result of the E2 binding with PDI b-b’
fragment. The distance is in angstroms. E2 is colored in blue and His256 is in magenta. Note that the amino acid residues of the b and b’ domains are
colored differently (black for the b domain and red for the b’ domain).
doi:10.1371/journal.pone.0027185.g003
Estradiol-Binding Site Structure of PDI
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addition, the computational model also suggests that 3-methox-
yestradiol might form a hydrogen bond with His256, but in this
case, the hydrogen bond would be very different from the
hydrogen bond formed with E2, i.e., the 3-methoxyestradiol serves
as a hydrogen bond acceptor while PDI-His256 serves as a
hydrogen bond donor (Figure 5C). However, experimental testing
of its binding activity for human PDI revealed that 3-methox-
yestradiol does not retain any appreciable binding activity
(Figure 5B). This observation suggests that the potential hydrogen
bond as predicted by the computational model likely is very weak
(of negligible significance). More importantly, the experimental
observation provides additional support for the predicted binding
model as shown in Figure 3, i.e., the hydrogen bond is formed in a
highly specific orientation between E2 and His256, with the former
serving as a hydrogen bond donor and the latter as a hydrogen
bond acceptor.
Discussion
We recently have characterized the E2-binding site structure of
human PDIp [26]. Overall, the human PDI and PDIp proteins
share similar E2-binding site structures, which are located in the
hydrophobic pocket composed mainly of the b’ domain and
partially of the b domain. Sequence alignment also shows
(Figure 6A) that overall the E2-binding sites of PDI and PDIp
are quite conserved and nearly located in the same region. The 3-
hydroxyl group of E2 is crucial for its binding interaction with both
PDI (Figures 3,4,5,6) and PDIp [26], through forming a hydrogen
bond with PDI-His256 and PDIp-His278, respectively. These two
histidine amino acids are conserved in these two proteins (as
indicated by the arrow in Figure 6A), but are not found in Erp57
and PDIA6, two other PDI family members that were recently
found to have no E2-binding activity [31]. In addition, the
hydrophobic amino acid residues inside the E2-binding pockets of
Figure 4. H256L mutant protein lacks E2-binding activity. (A) and (B). The [
3H]E2 binding by E. coli cell lysates containing the selectively-
expressed wild-type or H256L mutant DPI proteins (panel A) or by purified proteins (panel B) after incubation with 4.5 nM [
3H]E2 in the absence or
presence of non-radioactive E2 in excess (10 mM). Inset in panel A shows the SDS-PAGE analysis of the cell lysates. (C). The PDI-bound [
3H]E2 (wild-
type and H256L mutant proteins) against increasing concentrations of [
3H]E2 (200 to 3000 nM). Equilibrium analysis was used to determine the
binding activity as described in the Materials and Methods section. The concentrations of free and total [
3H]E2 (i.e., the sum of PDI-bound [
3H]E2 and
free [
3H]E2) were determined by scintillation counting calibrated against standard concentrations of [
3H]E2 (see Figure S2B).
doi:10.1371/journal.pone.0027185.g004
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binding through hydrophobic interactions. A contributing role of
the hydrophobic interactions in PDI-E2 binding is partly
supported by our experimental observation showing that Triton
X-100 (at low concentrations of ,0.02%, v/v), a commonly used
hydrophobic detergent, can effectively inhibit the E2-binding
activity of PDI and PDIp (data not shown).
Earlier studies using the NMR titration [28,32] and structure
analysis [33] have determined the peptide-binding site of PDI,
which was found to be located in a solvent-exposed hydrophobic
pocket [33]. The amino acid sequence alignment analysis of the
E2-binding site of PDI and its peptide-binding site (Figure 6A)
shows that there is only a limited degree of overlap between these
two binding sites. Mapping of these two sites in the three-
dimensional structure of PDI b-b’ fragment clearly shows that they
are very different with one another, suggesting that PDI likely
binds peptides and E2 in rather different fashions. Nevertheless,
the key amino acid residue for E2-binding, i.e., His256, appears to
be also involved in binding mastoparan (a peptide substrate) and
unfolded RNase A [28]. However, whether His256 forms a
hydrogen bond with the peptide substrate during its binding
interaction remains unknown at present.
It is known that the 3-hydroxyl group of E2 plays an essential
role in its binding interaction with human estrogen receptors a and
Figure 5. Relative binding activity of PDI for several E2 derivatives. (A). Chemical structures of E2 and several of its analogs used in this
study. (B). Relative binding activity of the purified PDI protein (at 20 mg/mL final concentration, purified from E. coli cells) for [
3H]E2 (4.5 nM) in the
absence or presence of non-radioactive 10 mME 2 or its analogs in sodium phosphate buffer (10 mM, pH 7.4). (C). Docking analysis of the binding
modes of E2 and C1 in the binding pocket of the PDI b-b’ fragment. Protein structure is shown in ribbon and colored in magenta. E2, C1 and His278
are shown in the ball-and-stick format. C1 and His 256 are colored according to atoms and E2 colored yellow. Green dashes denote hydrogen bonds.
a-Helics and b-sheets are labeled according to Figure S3.
doi:10.1371/journal.pone.0027185.g005
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structural model developed in the present study offers a reasonable
explanation for the experimental observations that the human PDI
has a much lower E2-binding affinity than human ERa and ERb.
First, human PDI forms only one hydrogen bond with the 3-
hydroxyl group of E2, whereas human ERa or ERb each can form
two hydrogen bonds with the 3-hydroxyl group. Second, while the
17b-hydroxyl group of E2 plays a negligible role in its binding
interaction with human PDI, this hydroxyl group plays an
important role in its interaction with human ERa or ERb [34].
Third, for both ERa and ERb, almost all amino acid residues in
their binding pockets, except those that form hydrogen bonds with
E2, are hydrophobic residues, which provide stronger hydrophobic
interactions with the four aliphatic rings of E2. However, in the
case of PDI, we noted that several polar residues (e.g., P235, K254,
H231, N232, K283, N214, E211, and K207; shown in Figure 3C,
Figure 6. Amino acid sequence alignment showing the overlap and difference between PDI’s E2-binding site and its peptide-
binding sites. (A) Sequence alignment was performed between human PDI and PPIp using Clustal W. The E2-binding sites of human PDI and PDIp,
which are colored in red, are based on the results of this study and our earlier study [26], respectively, along with the structural information for the
peptide-binding sites of PDI determined earlier by others (i.e., the NMR titration analysis of PDI-P1 [28] and PDI-P2 [32], and the structure analysis of
PDI-P3 [33]). The arrow indicates those highly-conserved amino acid residues, namely, His256 in PDI and His278 in PDIp, which are essential for their
binding interaction with E2. Based on an earlier study [28], the essential amino acid residue His256 in PDI is also involved in binding mastoparan (a
peptide substrate) and unfolded RNase A [28]. (B). Mapping the E2-binding site (left part) and peptide-binding site (right part) in the three-
dimensional structure of PDI b-b’ fragment. Peptide-binding sites include the combined residues from PDI-P1, PDI-P2, and PDI-P3 as shown in panel
A. Binding sites (red) are shown in the ball-and-stick format and the whole protein (white) in a cartoon format.
doi:10.1371/journal.pone.0027185.g006
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these polar residues may weaken the overall hydrophobic
interactions with E2.
Our results offer structural insights into the reservoir role of PDI
in modulating the intracellular levels and actions of E2 in
mammalian cells [12,14]. Although PDI has a much lower
binding affinity than human ERa and ERb [12,14], it is believed
that this intracellular protein still can store up considerable
amount of E2 inside a cell owing to its unusually high levels present
(as high as 100 mM, as estimated in an earlier study [12]). Our
recent study showed that the PDI-bound E2 molecules are
protected from metabolic disposition and can be further released
to augment ERa-mediated transcriptional activity in human
breast cancer cells [14]. Given that E2 has vital physiological
functions in humans [15,16] and that PDI is ubiquitously
expressed in various cells and tissues [17,18], it is speculated that
PDI may function as an important global modulator of the
intracellular E2 levels and actions in various target cells.
Additionally, since PDI can also bind thyroid hormones [11,12]
as well as other bioactive compounds such as endocrine disruptors
[13,19], it is possible that this protein may also modulate their
biological actions in a similar manner. This possibility merits
further investigation.
Lastly, it is of note that in recent years, PDI has received
considerable attention as a potential therapeutic target in cancer
chemotherapy [20,21] and HIV prevention [22–25]. The clinical
usefulness of some of the currently-available PDI inhibitors (such
as bacitracin), however, is limited due to the occurrence of
nephrotoxicity [37] as well as other adverse effects [38]. Although
several newer inhibitors, such as DTNB, pCMBS, PAO, aPAO,
and GSAO, have also been made in recent years, they have not
been used for therapeutic purposes, partly also due to the existence
of non-specific activities and adverse effects [7,25]. The E2-binding
site structure of human PDI as determined in our present study
provides detailed structural information concerning the binding
interactions of small non-peptide molecules with human PDI, and
this knowledge is expected to aid in the rational design of new PDI
inhibitors in the future. For instance, given that E2 is an effective
inhibitor of PDI activity in vitro [10,12,13,19], it is possible to
design novel E2-based structural analogs that lack estrogenic
activity but have a higher PDI inhibition potency through
rationally introducing additional hydrogen bonds, salt bridges,
and/or hydrophobic interactions with the amino acid residues in
the E2-binding pocket.
Materials and Methods
Chemicals, reagents, cell lines, and tissues
E2 and its structural analogs were purchased from Steraloids
(Newport, RI). [
3H]E2 (specific activity of 110 Ci/mmol) was
obtained from Perkin Elmer (Waltham, MA). All other chemicals
and reagents used in this study were of analytical grade or higher.
Plasmid construction and protein purification
Human PDI (its cDNA clone was obtained from ATCC, catalog
no. 6706839) was cloned into the pET-19b vector at the sites of 59-
NdeI/BamHI-39. The plasmids for the expression of histidine-
tagged PDI protein fragments (e.g., various a-b, b-b’, b, and b’
fragments) were constructed by cloning the corresponding cDNA
sequences into a modified pET-19b vector as described in our
earlier study [31]. Purification of the recombinant histidine-tagged
proteins expressed in E. coli was carried out as described earlier
[31,39]. The GST-tagged PDI b, b’ and b-b’ fragments (fusion
proteins) were cloned into a modified pGEX-4T-1 vector
containing the NdeI sites at 59-NdeI/SalI-39 and expressed in E.
coli and purified using the same chromatographic method [36,37].
Site-directed mutagenesis was performed using the PhusionH Site-
Directed Mutagenesis Kit obtained from the New England Biolabs
(Ipswich, MA, USA) according to the instructions of the
manufacturers.
Radiometric [
3H]E2-binding assay for cell lysates and
purified PDI proteins and fragments
For most of the in vitro radiometric binding assays, we employed
the desalting method to separate the free [
3H]E2 and protein-
bound [
3H]E2 as described in our recent study [26]. The full-
length human PDI protein and its various fragments were
individually incubated with [
3H]E2 (typically at a 4.5-nM final
concentration) in 10 mM sodium phosphate buffer (pH 7.4) at
4uC overnight and then subjected to desalting using the PD
miniTrap G-25 columns obtained from GE health. Eluted
fractions from 0.5 to 1.15 mL were collected for radioactivity
measurement.
However, for determining the dissociation constants (Kd values)
of the purified human PDI protein and its b-b’ fragment for
[
3H]E2, we used the equilibrium dialysis method. The experiments
were performed at 4uC using a single-sample DISPO equilibrium
dialyzer with a 5-kD molecular mass cut-off membrane obtained
from Harvard Apparatus (Holliston, MA, USA; catalog no. of
742201). The purified protein or fragment at appropriately diluted
concentrations was placed in one chamber of the dialyzer and
varying concentrations of [
3H]E2 were placed in a neighboring
chamber. The incubation lasted for 48 h, a sufficiently-long time
to ensure that the binding reached equilibrium, which was
determined in pilot experiments by following the binding
equilibrium time course (representative data are shown in Figure
S2).
Computational analysis of the E2 binding site and
molecular docking
The E2-binding site(s) in the human PDI b-b’ domain complex
(PDB code: 2k18) [28] was determined using the Active-Site-Search
function in the Binding-Site module of Insight II. The site-open-size
parameter was set at 5 A ˚ and the site-cut-off-size parameter was set
at 150 A ˚ 3. We defined the binding pocket with amino acid
residues within 5 A ˚ reach around the candidate binding site.
Simulated Annealing docking method in the Affinity module was used
to dock E2 into the candidate binding pocket. Water molecules
were excluded and side chains in the binding site were allowed to
move freely in the docking analysis. One hundred docking modes
were calculated and the ones with the lowest binding energy were
chosen for further energy minimizations.
Supporting Information
Figure S1 The single b and b’ domains lack [
3H]E2-
binding activity. (A). SDS-PAGE analysis of E. coli cell lysates
containing over-expressed GST-tagged PDI fragments. The
b’(BC)-x-a’-c and b’(C)-x-a’-c fragments represent the fragment b’-
x-a’-c lacking the secondary structural element A and AB of the b’
domain, respectively. Secondary structural elements are defined as
in the legend of Figure 1A. (B). SDS-PAGE analysis of E. coli cell
lysates containing selectively-expressed histidine-tagged b and b’
domains. (C). The binding of [
3H]E2 by whole cell lysates (at a
final concentration of 1 mg/ml in total proteins) after incubation
with 4.5 nM [
3H]E2 in the absence or presence of 10 mM non-
radioactive E2. Cell lysates containing the GST protein (left part)
Estradiol-Binding Site Structure of PDI
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value is the mean 6 S.D. of triplicate determinations.
(TIF)
Figure S2 Determination of optimal time and [
3H]E2
concentrations in equilibrium analysis. (A). Time-depen-
dent equilibrium of [
3H]E2 molecules in diffusing across the semi-
permeable membrane in the single-sample DISPO equilibrium
dialyzer at 4uC or at room temperature. Incubation at 4uC for
48 h appeared to be sufficient to reach the diffusion equilibrium.
(B). Correlation between the radioactivity of [
3H]E2 and concen-
trations of [
3H]E2 when performing the equilibrium analysis as
shown in Figure 2. The calibration curve was used to determine
the concentrations of free and total [
3H]E2 concentrations.
(TIF)
Figure S3 Determination of the potential cavities in PDI
for E2-binding. (A). Four cavities are identified in PDI b-b’
fragment by using the Active-Site-Search function in the Binding-Site
module of Insight II. Cavity I (yellow), II (gray), III (green), and IV
(brown) are colored differently in this figure for ease of recognition.
a-Helics and b-sheets are labeled according to their NMR
structures. (B). The structure shown in this panel is the same
structure as shown in panel A, but with a 90u horizontal rotation.
(TIF)
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